Centiva Capital LP Buys Shares of 18,630 Takeda Pharmaceutical Company Limited (NYSE:TAK)

Centiva Capital LP bought a new position in Takeda Pharmaceutical Company Limited (NYSE:TAK) in the third quarter, Holdings Channel.com reports. The firm bought 18,630 shares of the company’s stock, valued at approximately $265,000.

A number of other hedge funds also recently made changes to their positions in the stock. EverSource Wealth Advisors LLC boosted its position in Takeda Pharmaceutical by 38.6% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 3,082 shares of the company’s stock worth $43,000 after buying an additional 859 shares during the period. BNP Paribas Financial Markets raised its position in Takeda Pharmaceutical by 416.0% during the 3rd quarter. BNP Paribas Financial Markets now owns 3,220 shares of the company’s stock worth $46,000 after purchasing an additional 2,596 shares during the last quarter. Smithfield Trust Co lifted its holdings in Takeda Pharmaceutical by 76.9% during the 3rd quarter. Smithfield Trust Co now owns 3,428 shares of the company’s stock worth $49,000 after buying an additional 1,490 shares during the period. Erste Asset Management GmbH bought a new stake in shares of Takeda Pharmaceutical in the 3rd quarter valued at about $52,000. Finally, Headlands Technologies LLC acquired a new stake in shares of Takeda Pharmaceutical in the second quarter valued at about $59,000. 9.17% of the stock is currently owned by institutional investors and hedge funds.

Takeda Pharmaceutical Price Performance

Takeda Pharmaceutical stock opened at $13.57 on Thursday. The stock’s 50 day moving average is $13.86 and its 200 day moving average is $13.88. Takeda Pharmaceutical Company Limited has a one year low of $12.57 and a one year high of $15.08. The firm has a market cap of $43.16 billion, a P/E ratio of 23.39, a P/E/G ratio of 0.25 and a beta of 0.51. The company has a debt-to-equity ratio of 0.64, a current ratio of 1.28 and a quick ratio of 0.77.

Takeda Pharmaceutical Company Profile

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.